MX2022016548A - Muteínas de il-10 y proteínas de fusión de las mismas. - Google Patents

Muteínas de il-10 y proteínas de fusión de las mismas.

Info

Publication number
MX2022016548A
MX2022016548A MX2022016548A MX2022016548A MX2022016548A MX 2022016548 A MX2022016548 A MX 2022016548A MX 2022016548 A MX2022016548 A MX 2022016548A MX 2022016548 A MX2022016548 A MX 2022016548A MX 2022016548 A MX2022016548 A MX 2022016548A
Authority
MX
Mexico
Prior art keywords
muteins
antigen binding
fusion proteins
trem
compositions
Prior art date
Application number
MX2022016548A
Other languages
English (en)
Inventor
Hailing Hsu
Ming Zhang
Marissa Mock
Ian Foltz
Victor Mitch Luna
Sharon Wannberg
Tapia Gamze Ozlem Camdere
Timothy P Riley
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2022016548A publication Critical patent/MX2022016548A/es

Links

Classifications

    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J50/00—Circuit arrangements or systems for wireless supply or distribution of electric power
    • H02J50/005—Mechanical details of housing or structure aiming to accommodate the power transfer means, e.g. mechanical integration of coils, antennas or transducers into emitting or receiving devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La presente divulgación se refiere, en general, a muteínas de IL-10 que son estables como monómeros, a proteínas de unión a antígeno que se unen a TREM-1 y a proteínas de unión a antígeno que comprenden muteínas de IL-10 y restos de unión a antígeno, por ejemplo, anticuerpos anti-TREM-1 y composiciones de las mismas. La divulgación también proporciona métodos de tratamiento de enfermedades inflamatorias, tales como enteropatía inflamatoria o colitis ulcerosa, usando las composiciones.
MX2022016548A 2020-06-26 2021-06-25 Muteínas de il-10 y proteínas de fusión de las mismas. MX2022016548A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063045041P 2020-06-26 2020-06-26
US202063199218P 2020-12-14 2020-12-14
PCT/US2021/039191 WO2021263167A2 (en) 2020-06-26 2021-06-25 Il-10 muteins and fusion proteins thereof

Publications (1)

Publication Number Publication Date
MX2022016548A true MX2022016548A (es) 2023-03-14

Family

ID=77071744

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016548A MX2022016548A (es) 2020-06-26 2021-06-25 Muteínas de il-10 y proteínas de fusión de las mismas.

Country Status (16)

Country Link
US (1) US20230265145A1 (es)
EP (1) EP4172184A2 (es)
JP (1) JP2023531493A (es)
KR (1) KR20230027300A (es)
CN (1) CN116209459A (es)
AU (1) AU2021296917A1 (es)
CA (1) CA3187576A1 (es)
CL (1) CL2022003755A1 (es)
CO (1) CO2023000431A2 (es)
CR (1) CR20230025A (es)
IL (1) IL299149A (es)
MX (1) MX2022016548A (es)
PE (1) PE20231082A1 (es)
TW (1) TW202216743A (es)
UY (1) UY39298A (es)
WO (1) WO2021263167A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116425857B (zh) * 2023-06-09 2023-08-18 苏州依科赛生物科技股份有限公司 一种无糖基化修饰的il-15及制备方法
CN117143235B (zh) * 2023-10-26 2024-02-09 中国科学院苏州纳米技术与纳米仿生研究所 一种单克隆抗体及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
DE19851675A1 (de) * 1998-11-10 2000-05-11 Bayer Ag Menschliche Interleukin-10 Mutantenproteine
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
HU228477B1 (en) 1999-08-23 2013-03-28 Dana Farber Cancer Inst Inc Pd-1, a receptor for b7-4, and uses therefor
DK2206517T3 (da) 2002-07-03 2023-11-06 Ono Pharmaceutical Co Immunpotentierende sammensætninger omfattende af anti-PD-L1-antistoffer
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
CA2607147C (en) 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
JP5252635B2 (ja) 2005-07-01 2013-07-31 メダレックス インコーポレーティッド プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
JP2012501670A (ja) 2008-09-12 2012-01-26 アイシス・イノベーション・リミテッド Ｐｄ−１特異抗体およびその使用
EP3133086B1 (en) 2008-09-26 2018-08-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
LT4209510T (lt) 2008-12-09 2024-03-12 F. Hoffmann-La Roche Ag Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
CN104837865B (zh) 2012-09-07 2019-09-24 国立健康与医学研究所 衍生自髓样细胞触发受体-1(trem-1)trem-样转录物1(tlt-1)的抑制肽及其用途
WO2014176373A2 (en) * 2013-04-24 2014-10-30 Armo Biosciences, Inc. Interleukin-10 compositions and uses thereof
US10512672B2 (en) * 2013-07-18 2019-12-24 Xalud Therapeutics, Inc. Methods for the treatment of inflammatory joint disease
CN112457403B (zh) 2013-09-13 2022-11-29 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
RU2016135788A (ru) * 2014-02-06 2018-03-07 Ф.Хоффманн-Ля Рош Аг Иммуноконъюгаты интерлейкина 10
US11472877B2 (en) * 2016-03-04 2022-10-18 Alector Llc Anti-TREM1 antibodies and methods of use thereof
JOP20200172A1 (ar) 2018-01-12 2020-07-12 Amgen Inc الأجسام المضادة لـ pd-1 وطرق العلاج

Also Published As

Publication number Publication date
WO2021263167A3 (en) 2022-04-21
AU2021296917A1 (en) 2023-02-02
UY39298A (es) 2022-01-31
KR20230027300A (ko) 2023-02-27
WO2021263167A2 (en) 2021-12-30
PE20231082A1 (es) 2023-07-17
CN116209459A (zh) 2023-06-02
JP2023531493A (ja) 2023-07-24
TW202216743A (zh) 2022-05-01
EP4172184A2 (en) 2023-05-03
CA3187576A1 (en) 2021-12-30
CO2023000431A2 (es) 2023-03-27
CL2022003755A1 (es) 2023-07-21
IL299149A (en) 2023-02-01
US20230265145A1 (en) 2023-08-24
CR20230025A (es) 2023-10-05

Similar Documents

Publication Publication Date Title
EA202092417A1 (ru) Химерные рецепторы к dll3 и способы их применения
MY146664A (en) Antibodies against human il-22 and uses therefor
EA201000471A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
CR20230025A (es) Muteínas de il-10 y proteínas de fusión de las mismas referencia cruzada a solicitudes relacionadas
MX2009012493A (es) Metodos de humanizacion de anticuerpo de conejo novedosos y anticuerpos de conejo humanizados.
PH12014502527B1 (en) St2 antigen binding proteins
PH12013502205A1 (en) Antibodies to il-6 and their uses
MX2010002269A (es) Composiciones y metodos que comprenden proteinas de union para adalimumab.
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
RS53042B (en) ANTIBODIES AGAINST ERBB3 AND THEIR USES
MX2022000325A (es) Anticuerpos dirigidos contra dll3 y usos de los mismos.
TW200744634A (en) Methods of using antibodies against human IL-22
MX2016012479A (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
EA201290589A1 (ru) Cd127-связывающие белки
MX2022015157A (es) Anticuerpos para tigit.
MX2022007288A (es) Agentes de union a ilt3 y metodos de uso de los mismos.
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
CR20210091A (es) Receptores químericos de steap1 y métodos de uso de los mismos antecedentes de la invención
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
MX2021009975A (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer.
CR20230245A (es) Moléculas de unión a gucy2c y sus usos
MX2023005386A (es) Anticuerpos monoclonales dirigidos contra la proteina de muerte programada-1 y su uso en medicina.
MX2021014882A (es) Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.
EA202191821A1 (ru) Группы, связывающие клаудин 18.2, и их использование
WO2023023489A3 (en) Bispecific anti-flt3/cd3 antibodies and methods of use